617 results on '"Suárez-Calvet, Marc"'
Search Results
2. APOE4 homozygosity represents a distinct genetic form of Alzheimer’s disease
3. Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer’s disease
4. Atypical cortical hierarchy in Aβ-positive older adults and its reflection in spontaneous speech
5. APOE-ε4 modulates the association between regional amyloid deposition and cognitive performance in cognitively unimpaired middle-aged individuals
6. Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts
7. Identifying clinically useful biomarkers in neurodegenerative disease through a collaborative approach: the NeuroToolKit
8. Reactive astrogliosis is associated with higher cerebral glucose consumption in the early Alzheimer’s continuum
9. Early increase of CSF sTREM2 in Alzheimer’s disease is associated with tau related-neurodegeneration but not with amyloid-β pathology
10. Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease
11. Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility
12. The mediating role of neuroimaging-derived biological brain age in the association between risk factors for dementia and cognitive decline in middle-aged and older individuals without cognitive impairment: a cohort study
13. Age, sex and APOE-ε4 modify the balance between soluble and fibrillar β-amyloid in non-demented individuals: topographical patterns across two independent cohorts
14. Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer’s disease
15. CSF progranulin increases in the course of Alzheimer's disease and is associated with sTREM2, neurodegeneration and cognitive decline
16. White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimer’s disease
17. Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study
18. Subjective cognitive decline and anxious/depressive symptoms during the COVID-19 pandemic: what is the role of stress perception, stress resilience, and β-amyloid?
19. Genetically predicted telomere length and Alzheimer’s disease endophenotypes: a Mendelian randomization study
20. Time‐encoded ASL reveals lower cerebral blood flow in the early AD continuum.
21. Memory performance mediates subjective sleep quality associations with cerebrospinal fluid Alzheimer's disease biomarker levels and hippocampal volume among individuals with mild cognitive symptoms.
22. NeuroToolKit Data Hackathon: advancing data collaboration in Alzheimer’s disease.
23. Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimer’s disease
24. A blood‐based multi‐pathway biomarker assay for early detection and staging of Alzheimer's disease across ethnic groups
25. Amyloid-β positive individuals with subjective cognitive decline present increased CSF neurofilament light levels that relate to lower hippocampal volume
26. The BDNFVal66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer’s disease
27. Awareness of episodic memory and meta-cognitive profiles: associations with cerebrospinal fluid biomarkers at the preclinical stage of the Alzheimer's continuum.
28. Lifetime Stressful Events Associated with Alzheimer's Pathologies, Neuroinflammation and Brain Structure in a Risk Enriched Cohort.
29. Association of human brain‐age with genetically predicted plasma levels of brain rejuvenating and aging factors identified in mice
30. Reproductive span as a modifier of the association between AD biomarkers and cognitive decline in cognitively unimpaired women
31. Associations between NIH‐Toolbox Flanker test and the Picture Sequence Memory Test and multimodal Alzheimer’s disease biomarkers in cognitively unimpaired individuals
32. Optimizing plasma biomarkers combinations for the detection of amyloid pathology in cognitively unimpaired individuals
33. A novel ultrasensitive assay for plasma p‐tau217: Performance in individuals with subjective cognitive decline and early Alzheimer's disease
34. Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimer’s disease
35. Publisher Correction: Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease
36. Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline
37. An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders
38. APOE4homozygosity represents a distinct genetic form of Alzheimer’s disease
39. Genetic characterization of the ALFA study: Uncovering genetic profiles in the Alzheimer's continuum.
40. A novel ultrasensitive assay for plasma p‐tau217: Performance in individuals with subjective cognitive decline and early Alzheimer's disease.
41. Risk of cognitive decline progression is associated to increased blood‐brain‐barrier permeability: A longitudinal study in a memory unit clinical cohort.
42. Risk of cognitive decline progression is associated to increased blood‐brain‐barrier permeability: A longitudinal study in a memory unit clinical cohort
43. Longitudinal interplay between subclinical atherosclerosis, cardiovascular risk factors, and cerebral glucose metabolism in midlife: results from the PESA prospective cohort study
44. NEURONORMA Cognitive Battery Associations with Cerebrospinal Fluid Amyloid-β and Tau Levels in the Continuum of Alzheimer’s Disease
45. Biological brain age prediction using machine learning on structural neuroimaging data: multi-cohort validation against biomarkers of Alzheimer's disease and neurodegeneration stratified by sex
46. The APOE ε4 genotype modulates CSF YKL-40 levels and their structural brain correlates in the continuum of Alzheimer's disease but not those of sTREM2
47. Spatial patterns of white matter hyperintensities associated with Alzheimer’s disease risk factors in a cognitively healthy middle-aged cohort
48. Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers
49. Differential effects of sleep on brain structure and metabolism at the preclinical stages of AD.
50. Biological brain age prediction using machine learning on structural neuroimaging data:Multi-cohort validation against biomarkers of Alzheimer's disease and neurodegeneration stratified by sex
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.